TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: nocturnal SBP lowering
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with 5% postoperative weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nurse competence level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability (treatment related (serious) adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: hypocalcemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: patent ductus arteriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: retinopathy of prematurity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Averaged Mean Far Wall Common Carotid Artery Intima-media Thickness (cIMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Measured Concentration of the Hyoscine Butylbromide in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of the Hyoscine Butylbromide in Plasma (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnetic Resonance Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurological Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bleeding Within 30 Days
Endpoint domain: Adverse events/effects
Primary endpoint: Outcomes of Cardiogenic shock patients
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Amebiasis and Cryptosporidium infection
Endpoint domain: Adverse events/effects
Primary endpoint: sensitivity and specificity percentages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1,3,5 Year-Disease Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Posttraumatic Stress Disorder Checklist-Stressor-specific Version (PCL-S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Absolute Change in the Inflammatory Lesion Counts on the Face
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Absolute Change in the Non-inflammatory Lesion Counts on the Face
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of Subjects With Treatment Success Based on IGA Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: WBCT measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance between activation and rest activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Objective Response Rate (Independent Review Committee Assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (Investigators Assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti Xa level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Participant's Assessment of Global Pain Intensity
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Delay discounting of money rate (k)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAM score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuroinflammation in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in ASIA Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recommended Phase 2 Dose (RP2D) of TL-895
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical activity: accelerometer counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical activity: Community Healthy Activities Model Program for Seniors (CHAMPS) survey
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of major infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Circulating Tumor Cell (CTC) Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Anxiety of familial caregivers
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Individual Innovativeness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Critical Thinking Trends
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Success Test
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Coronary plaque vulnerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incident risk of COVID-19 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants tumour-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in EEG Power of Slow Wave Oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hypoadiponectinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in plasma lipid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects with dose reduction of cabozantinib due to SAEs/AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with dose interruption of cabozantinib and/or nivolumab due to SAEs/AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with termination of cabozantinib/cabozantinib-nivolumab combination due to SAEs/AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of injection delayed of nivolumab due to SAE/AE
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of 13C in plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum tolerated dose of BPX-101 and AP1903
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of BPX-101 and AP1903
Endpoint domain: Adverse events/effects
Primary endpoint: Difficult airway prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivities of omics signatures for the diagnosis of subtypes of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificities of omics signatures for the diagnosis of subtypes of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tremor Rating Scale (TRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients maintaining HBV DNA <1.5 X the upper limit of normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Difference Between Morning and Non-Morning Log White Blood Cell (WBC) Cystine Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Record of Bleeding Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Glycemic level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Persistent Postoperative Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Working memory training performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients persistence to the index medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Urine Toxicology for Cocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: self-reported xerostomia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Antibiotic Therapy Duration (in Days) Per Participant for Home Infusion Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Treatment Goals Met at End of Therapy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Knee Injury and Osteoarthritis Outcome Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum Tolerated Dose(s) MTD(s) of BLYG8824A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Positive predictive value (PPV) of the ParaNASPP model
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in MRI signal intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tidal volume measured by spirometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of DBS surgery for movement disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Individuals With Successful Opening of the BBB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Safety Events Related to Opening of BBB
Endpoint domain: Adverse events/effects
Primary endpoint: Elbow Extension-Flexion Arc of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in binge and loss-of-control eating episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of resolution of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants Seroprotected Against HAV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Sexual Function
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in linguistic interpretation bias
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in visual interpretation bias
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Successful Performance Rate of Device Features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre- and post-operative hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neurocognitive status
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cell Yield ≥ 3 x 10e6 CD34+/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve for glucagon-like peptide I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Need for inotropic agents or IABP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximal Isometric Force in the Knee Extensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Assessment of change in Muscle Cross-Sectional Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: LV myocardial efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pelvic tilting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of antihypertensive medication fills
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Down-staging of the Tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response to Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Trace elements concentration in TPN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease in PASI Score at EOT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-tau) of norelgestromin and ethinylestradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average numbers of visits required to start ART
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: RP2D defined as highest dose level with dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Difference between SpHb and tHb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Mean Number of Nocturnal Voids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of canagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) for canagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) for metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour urine glucose excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Length of Post Anesthesia Care Unit (PACU) stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Pain (Visual Analog Scale) VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Pressure upon PACU discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: systolic blood pressure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants deceased
Endpoint domain: Mortality/survival
Primary endpoint: Intra-dialytic hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Provider decision making heuristics
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Formal and informal norms influencing provider decision making
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: PET based radiotherapeutic treatment planning parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: rate of short term complications
Endpoint domain: Adverse events/effects
Primary endpoint: rate of long term complications
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of acute graft-versus-host disease (GVHD) II-IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time at which first-phase viral decay begins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Remission of infection
Endpoint domain: Adverse events/effects
Primary endpoint: VAS score visual acoustic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic inflammation (hsCRP, Interleukin-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Success of segmental resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Beck Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Standardized BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cost-effectiveness (full economic analysis)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of Lower Calorie products in shopping basket
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 24-Week Progression-Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Dopamine receptor regional binding potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Femoral rotations and translations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinician Administered PTSD scale (CAPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BAT metabolic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity for CRC of the Freenome test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of the Freenome test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Return to hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean scores of Instrumental Activities of Daily Living (IADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of urine metabolomics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Thrombocythemia kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With no Acute Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients With Donor-derived Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain during activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain at night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator's Global Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician's Wart Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cerebral networks measured by fMRI mediating body perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: brain activation during own body perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: morphometric differences by sex, gender identity and sexual orientation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Score of Patient Satisfaction With Injection Experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Observed Drug Concentration (Cmax) of Cytochrome P450 Substrate-Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of CYP450 Substrate-Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Powered Mobility Program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Learning Powered Mobility Use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Israel Ministry of Health Proficiency Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevention of heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cost effectiveness of Spironolactone prevention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline in clinical institute narcotic assessment scale (CINA) for withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Understanding evaluation at day 5
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Satisfaction scale out of intensive care
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in average osteoarthritis-related pain intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of APLA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Placebo analgesic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urea and creatinine levels in vaginal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in neurocognitive performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: brain malignancy volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients with HBsAg negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of Patients With Superficial Site Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Time to achieve glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants with Clinical Response at Week 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Clinical Remission at Week 60
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' functioning assessed by the Sheehan Disability Scale (SDS) total score
Endpoint domain: Life impact
Endpoint subdomain: Functional functioning
Primary endpoint: incision time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incision blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes